Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beyer, D. Articles by Brötz-Oesterhelt, H. Search for Related Content PubMed PubMed Citation Articles by Beyer, D. Articles by Brötz-Oesterhelt, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 525-532, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.525-532.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

New Class of Bacterial Phenylalanyl-tRNA Synthetase Inhibitors with High Potency and Broad-Spectrum Activity

Dieter Beyer,¹ Hein-Peter Kroll,¹ Rainer Endermann,¹ Guido Schiffer,¹ Stephan Siegel,² Marcus Bauser,² Jens Pohlmann,² Michael Brands,² Karl Ziegelbauer,¹ Dieter Haebich,² Christine Eymann,³ and Heike Brötz-Oesterhelt^1*

Department of Anti-Infectives,¹ Department of Chemistry, Pharma Research, Bayer Healthcare AG, D-42096 Wuppertal,² Institute for Microbiology, Ernst-Moritz-Arndt-University, 17489 Greifswald, Germany³

Received 27 May 2003/ Returned for modification 24 August 2003/ Accepted 14 October 2003

Top Abstract Introduction Materials and Methods Results Discussion References

 
Phenylalanyl (Phe)-tRNA synthetase (Phe-RS) is an essential enzyme which catalyzes the transfer of phenylalanine to the Phe-specific transfer RNA (tRNA^Phe), a key step in protein biosynthesis. Phenyl-thiazolylurea-sulfonamides were identified as a novel class of potent inhibitors of bacterial Phe-RS by high-throughput screening and chemical variation of the screening hit. The compounds inhibit Phe-RS of Escherichia coli, Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus, with 50% inhibitory concentrations in the nanomolar range. Enzyme kinetic measurements demonstrated that the compounds bind competitively with respect to the natural substrate Phe. All derivatives are highly selective for the bacterial Phe-RS versus the corresponding mammalian cytoplasmic and human mitochondrial enzymes. Phenyl-thiazolylurea-sulfonamides displayed good in vitro activity against Staphylococcus, Streptococcus, Haemophilus, and Moraxella strains, reaching MICs below 1 µg/ml. The antibacterial activity was partly antagonized by increasing concentrations of Phe in the culture broth in accordance with the competitive binding mode. Further evidence that inhibition of tRNA^Phe charging is the antibacterial principle of this compound class was obtained by proteome analysis of Bacillus subtilis. Here, the phenyl-thiazolylurea-sulfonamides induced a protein pattern indicative of the stringent response. In addition, an E. coli strain carrying a relA mutation and defective in stringent response was more susceptible than its isogenic relA⁺ parent strain. In vivo efficacy was investigated in a murine S. aureus sepsis model and a S. pneumoniae sepsis model in rats. Treatment with the phenyl-thiazolylurea-sulfonamides reduced the bacterial titer in various organs by up to 3 log units, supporting the potential value of Phe-RS as a target in antibacterial therapy.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Resistance to multiple antibiotics is spreading throughout the world, seriously challenging our ability to treat bacterial infections (42). Staphylococcus aureus, for instance, is one of the leading causes of threatening nosocomial infections (18), especially since the increasing reliance on vancomycin has led to the emergence of isolates exhibiting intermediate or even high-level glycopeptide resistance (27, 37). A further example is Streptococcus pneumoniae, an important pathogen in community-acquired respiratory tract infections that has developed a high degree of ß-lactam and macrolide resistance (2). In addition to the requirement for a more judicious use of our current collection of antibiotics, there is a critical need for compounds with no cross-resistance to commonly prescribed antibiotics.

Aminoacyl-RSs (aa-RSs) attracted interest as potential novel targets in bacterial protein synthesis, because they are indispensable for the highly specific translation of the mRNA template into protein via specific transfer RNAs (tRNAs) as adapter molecules (16, 36). In the present study we focused on phenylalanyl (Phe)-tRNA synthetase (Phe-RS), which is responsible for coupling the amino acid Phe to the corresponding Phe-specific tRNA (tRNA^Phe) (4). The catalytic reaction proceeds in two steps and includes, first, the activation of Phe by adenylation, yielding Phe-AMP as an intermediate, and, subsequently, the transfer of the amino acid to the 3' end of the cognate tRNA^Phe (4). The charged Phe-tRNA^Phe is then able to interact with the elongation factor Tu and with the ribosomal A site to elongate the nascent protein chain.

Most organisms possess 20 aa-RSs, one for each amino acid, which are classified into two structurally distinct classes on the basis of typical consensus motifs (39). Phe-RS shows some unique characteristics. First, it is one of the largest aa-RSs known and has an exceptional ₂ß₃ quaternary structure, which appears only in Phe-RS and Gly-RS (28). Furthermore, Phe-RS is the only class II enzyme which attaches the amino acid to the 2'OH group of the tRNA's 3'-terminal ribose (14). Analysis of the crystal structure of Phe-RS alone and in complex with its substrates and a Phe-AMP analog revealed that the -subunit contains the catalytic center and that the ß-subunit is involved in binding of the tRNA (17, 28, 31). The sequences of bacterial Phe-RSs are well conserved (39) but differ significantly from those of their eukaryotic counterparts (32). As Phe-RS is indispensable for growth in all organisms, this suggests an interesting target for antibacterial therapy.

Only one aa-RS inhibitor, the Ile-RS inhibitor mupirocin, is currently marketed as an antibacterial agent (Bactoban). Due to its labile ester bond, the use of mupirocin (also known as pseudomonic acid) (15) has been limited to the treatment of topical infections (3). However, no Phe-RS inhibitor useful as an antibiotic agent against systemic infections has been described so far. Studies from the 1970s report a 50% inhibitory concentration (IC₅₀) value for N-benzyl-D-amphetamine of 140 nM for the Phe-RS of Escherichia coli and 20-fold-lower activity against the corresponding enzyme from rat liver (1, 35). For ochratoxin, the food-contaminating mycotoxin, inhibition of Phe-RS was initially discussed as a possible mechanism of toxicity (23). Subsequent investigators question this interpretation, nevertheless, as the concentration of ochratoxin in Bacillus subtilis appears to be too low to significantly compete with phenylalanine for the binding site of Phe-RS (33). For other aa-RS enzymes several inhibitors have been patented and reported in the literature over the years (6, 16, 40), but none of them has been developed as an antibacterial agent so far.

Here we describe the phenyl-thiazolylurea-sulfonamides as a novel class of Phe-RS inhibitors. These compounds inhibit Phe-RSs of gram-positive and gram-negative bacteria, with IC₅₀s in the nanomolar range and high levels of specificity for the bacterial versus the mammalian cytoplasmic and the mitochondrial proteins. In vitro and in vivo data support the potential use of this compound class and the value of Phe-RS as an antibacterial target.

(This material was presented in part at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 27 to 30 September 2002 [D. Beyer, H.-P. Kroll, M. Bauser, S. Siegel, H. Brötz, R. Endermann, G. Schiffer, K. Ziegelbauer, D. Häbich, and J. Pohlmann, abstr. F-756, and H. Brötz, R. Endermann, G. Schiffer, M. Bauser, J. Pohlmann, D. Beyer, H.-P. Kroll, K. Ziegelbauer, D. Häbich, and S. Siegel, abstr. F-757]).

Top Abstract Introduction Materials and Methods Results Discussion References

 
Strains and antibiotics. S. aureus 133, S. pneumoniae G9A, S. pneumoniae 1707/4, Haemophilus influenzae Spain 7, and Moraxella catarrhalis 489 are clinical isolates (purified and identified according to standard procedures) from human infections. S. aureus 133 is deposited with the number DSM11832 at the Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany. E. coli CP78 and CP79 are an isogenic pair of laboratory strains (a relA⁺ strain and a strain carrying a mutated relA gene, respectively) (12). Phenyl-thiazolylurea-sulfonamides were synthesized at Bayer, and mupirocin was provided by Glaxo-Smith-Kline. All other antibiotics used in this study were obtained from Sigma-Aldrich.

Susceptibility testing. MICs were determined by broth microdilution in synthetic glucose-salt medium with an inoculum of 10⁵ CFU/ml. After incubation for 18 h at 37°C, MICs were read as the lowest concentrations of compounds that prevented visible bacterial growth. Streptococci and Haemophilus strains were incubated in the presence of 10% CO₂; all other strains were incubated in ambient air. For S. pneumoniae, H. influenzae, and M. catarrhalis, C-DEN medium similar to the streptococcal medium described previously (24) but without any complex ingredients to adjust the Phe concentration was used. The C-DEN medium contained the following ingredients (per liter): 6.3 g of K₂HPO₄, 0.28 g of KH₂PO₄, 1.2 g of sodium acetate, 2.05 g of NaCl, 0.22 g of MgCl₂, 1.9 g of glucose, 0.23 g of sucrose, 0.25 g of pyruvate, 0.09 g of alanine, 0.1 g of arginine, 0.05 g of asparagine, 0.19 g of aspartic acid, 0.04 g of cysteine, 0.57 g of glutamic acid, 0.03 g of glutamine, 0.05 g of glycine, 0.08 g of histidine, 0.2 g of isoleucine, 0.25 g of leucine, 0.23 g of lysine, 0.08 g of methionine, 0.3 g of proline, 0.15 g of serine, 0.12 g of threonine, 0.04 g of tryptophan, 0.02 g of tyrosine, 0.19 g of valine, 2.3 mg of CaCl₂, 0.014 mg of MnSO₄, 19 mg of adenosine, 19 mg of uridine, 5 mg of choline, 0.02 mg of biotin, 0.6 mg of nicotinic acid, 0.7 mg of pyridoxine HCl, 2.5 mg of calcium pantothenate, 0.7 mg of thiamine HCl, and 0.3 mg of riboflavin. For S. pneumoniae, the medium was supplemented with 10 g of choline/liter and 20 mg of yeast extract/liter; for H. influenzae, the medium was supplemented with 10 g of IsoVitale X (Becton-Dickinson)/liter and 10 g of hemin/liter. For S. aureus and E. coli, a somewhat simpler minimal medium with the following ingredients (per liter) was used: 3.3 g of Na₂HPO₄, 1 g of KH₂PO₄, 1 g of NaCl, 0.5 g of NH₄Cl, 0.34 g of MgSO₄, 10 g of glucose, 1.2 mg of nicotinic acid, 0.03 mg of thiamine, 0.003 mg of biotin, and 25 µg of each amino acid (except phenylalanine)/ml. For E. coli CP78 and CP79, the medium was supplemented with 4 g of brain heart infusion/liter, 4 mg of thiamine/liter, and 25 mg of polymyxin B nonapeptide (Sigma-Aldrich)/liter as permeabilizer of the outer membrane. For MIC testing in the presence of various Phe concentrations, cultures were grown to the exponential growth phase in medium containing 8.3 mg of Phe/liter and then diluted into fresh medium with the desired Phe concentration.

Time-kill study. S. pneumoniae G9A was grown in C-DEN medium supplemented with 10 g of choline/liter and 20 mg of yeast extract/liter at 37°C in the presence of 10% CO₂. The medium was inoculated with 3 x 10⁶ CFU/ml, and the number of CFU was monitored for 6 h after the addition of compound. Colony counts were determined by plating culture aliquots on compound-free Columbia blood agar.

Cytotoxicity assay. Chinese hamster ovary cells (5 x 10⁴ cells/ml) were cultured in 200 µl of RPMI 1640 medium with glutamic acid (Gibco)-10% fetal calf serum in 96-well microtiter plates for 24 h at 37°C and 5% CO₂. Cells were then incubated for 24 h in fresh medium supplemented with the test compounds in a serial twofold-dilution series. After removal of the compounds, cells were grown in fresh medium for a further 48 h. Subsequently, cells were stained by adding 80 µl of a solution of 4',6-diamidino-2-phenylindole-dihydrochloride (Sigma-Aldrich) (2.5 µg/ml in water) and incubated for 1 additional hour at 37°C and 5% CO₂. Cell viability was determined by fluorescence measurement at an excitation wavelength of 360 nm and an emission wavelength of 465 nm.

Isolation of Phe-RS proteins. Cultures of S. aureus 133 were grown in Luria broth supplemented with 0.2% (wt/vol) glucose. S. pneumoniae G9A and H. influenzae Spain 7 were cultured in C-DEN medium and incubated in the presence of 10% CO₂. For preparations of subcellular fractions, cultures were grown at 37°C up to an optical density at 578 nm of 0.5. Cells were harvested by centrifugation (5,000 x g, 7 min, 4°C), washed three times in 50 ml of preparation buffer (10 mM Tris-HCl [pH 7.5], 6 mM MgCl₂, 30 mM NH₄Cl, 4 mM 2-mercaptoethanol) and centrifuged again (8,000 x g, 10 min, 4°C). Cells were resuspended in 1 ml of preparation buffer per gram (wet weight). Phenylmethanesulfonyl fluoride (0.5 mM) was added to avoid protein degradation. Cells were disrupted by four French Press Cell (Sim Aminco SLM Instruments Inc.) passages at 14,000 lb/in². The cell lysate was precipitated by centrifugation (8,000 x g, 10 min, 4°C). The supernatant was subjected to centrifugation (9,000 x g, 30 min, 4°C) followed by a second centrifugation for 18 h at 3,000 x g. The supernatant was decanted and dialyzed three times for 1 h with 1 liter of preparation buffer. All enzymes were shock frozen in liquid nitrogen and stored at -80°C. E. coli protein purified to homogeneity was obtained from M. Ibba (Ohio State University, Columbus). Human mitochondrial Phe-RS was isolated according to Bullard et al. (8), and rabbit reticulocyte lysate was purchased from Promega.

Phe-RS inhibition studies. The Phe-tRNA aminoacylation reaction was determined by ethanol precipitation of ¹⁴C-labeled tRNA^Phe (9, 29). The assay was performed by incubation of [¹⁴C]Phe with cell extracts in 180 mM HEPES (pH 7.6)-20 mM magnesium acetate-10 mM glutathione-7.5 mM ATP-0.2 mM CTP-0.1 U of tRNA^E.coli (Sigma-Aldrich)-1% dimethyl sulfoxide in a final volume of 75 µl for 20 min at room temperature. The reaction product ([¹⁴C]Phe-tRNA) was separated from the [¹⁴C]Phe by precipitation with 200 µl of ethanol followed by 30 min of incubation at 4°C and subsequent filtration through a GF/C 96-well plate (Packard). Filter-bound radioactivity was detected with a scintillation counter. [¹⁴C]Ile was used instead of [¹⁴C]Phe for control experiments with mupirocin. IC₅₀s correspond to the concentration at which half of the enzyme activity is inhibited by the compound.

Proteome analysis. B. subtilis 168 was grown in Belitzky minimal medium in the presence of compound 1 at concentrations of 0.25 and 0.5 µg/ml, representing 0.5 and 1 times the MIC, respectively. At 10 and 20 min after the addition of the antibiotic, samples were pulse labeled with [³⁵S]methionine. Growth and labeling conditions, as well as the procedure for two-dimensional polyacrylamide gel electrophoresis and data analysis, were described previously (5).

Systemic infection. For the S. aureus 133 sepsis procedure, an exponentially growing culture was diluted in 5% mucin-0.9% NaCl to the final challenge dose of 10⁶ bacteria per mouse. Female CFW1 mice were infected by injecting the bacterial suspension into the peritoneal cavity and were treated once intravenously (i.v.) 0.5 h after infection. Organs were removed aseptically 3 h after infection and homogenized, and the bacterial titer was determined by plating. One group of mice was fed on a phenylalanine-free diet (FSS333905; Ssniff, Soest, Germany) for 5 days prior to infection, reducing the phenylalanine concentration in the plasma to one-fifth of the normal level (i.e., that seen with mice on a normal diet) (FSS333906; Ssniff). Determination of the Phe level in the murine plasma was performed according to the method of Liu (25). For the S. pneumoniae 1707/4 sepsis investigations, young Wistar rats were infected intraperitoneally (i.p.) with a challenge dose of 3 x 10⁵ bacteria per animal and were treated twice i.p. 0.5 and 3 h after infection. The bacterial load in the organs was determined 6 h after infection.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Compound discovery and enzymatic activity against the target. High-throughput screening of our compound library identified several inhibitors of the E. coli Phe-RS enzyme. During the lead optimization process, the compounds were tested for inhibition of Phe-RS derived from different gram-negative pathogens (E. coli and H. influenzae) as well as from gram-positive pathogens (S. aureus and S. pneumoniae). Chemical optimization of initially detected compounds resulted in the phenyl-thiazolylurea-sulfonamides as strong Phe-RS inhibitors (Fig. 1). These compounds demonstrated strong activity against Phe-RS derived from gram-negative organisms with IC₅₀s in the nanomolar range (Table 1). For example, compound 7 showed IC₅₀s of <5 and 10 nM with the enzymes from E. coli and H. influenzae, respectively. With the Phe-RS of gram-positive pathogens, these compounds were slightly less potent. For instance, the IC₅₀ values of the most potent compounds (compounds 4 and 5) with Phe-RS derived from S. pneumoniae were 50 nM and 40 nM, respectively (Table 1). Exemplary congeners were also tested with Phe-RS in cell extracts of S. aureus. Compounds 2 and 3 yielded IC₅₀s of 50 and 80 nM, respectively.

View larger version (27K): [in this window] [in a new window]

FIG. 1. Chemical structures of the phenyl-thiazolylurea-sulfonamides discussed in this study.

View this table: [in this window] [in a new window]

TABLE 1. Inhibition of different bacterial Phe-RS enzymes by the phenyl-thiazolylurea-sulfonamides

Selectivity. Both the mammalian cytoplasmic Phe-RS and the mitochondrial Phe-RS were investigated independently to determine selectivity. To analyze the effect on the cytoplasmic Phe-RS, we used a rabbit reticulocyte lysate (Table 2). No inhibition was detected at compound concentrations of up to 200 µM. In the case of purified human-mitochondrial Phe-RS, inhibition was observed only at high phenyl-thiazolylurea-sulfonamide concentrations with IC₅₀s of 10 µM (Table 2). In addition, when compounds 2, 5, and 6 were analyzed in a cytotoxicity assay with Chinese hamster ovary cells, IC₅₀s were above the highest concentrations tested (160 µg/ml).

View this table: [in this window] [in a new window]

TABLE 2. Selectivity of the phenyl-thiazolylurea-sulfonamides

Phe-RS binding mode. In enzyme kinetic measurements with purified E. coli Phe-RS, the phenyl-thiazolylurea-sulfonamides inhibited the aminoacylation of tRNA^Phe competitively with respect to the substrate Phe (Fig. 2A). The Michaelis-Menten constant (K_m = 1.9 µM) with Phe in the concentration range from 1 to 16 µM was close to the previously reported value (K_m = 1.5 µM) (21). We measured the inhibitory constant K_i of compound 2 as a representative of the phenyl-thiazolylurea-sulfonamides. The K_i value (21 nM) was 2 orders of magnitude lower than the K_m value of Phe. In contrast, noncompetitive binding was observed with respect to the second substrate, ATP. Increasing ATP concentrations did not reverse the inhibitory effect of compound 2 (Fig. 2B).

View larger version (20K): [in this window] [in a new window]

FIG. 2. Inhibition of E. coli Phe-RS by compound 2. The rate of Phe-tRNA formation was determined at room temperature over 20 min. (A) Competitive binding with respect to Phe. Compound 2 concentrations were as follows: 0 µM (), 0.04 µM (), and 0.156 µM (). The inset shows results in the form of a Lineweaver-Burk plot (Km for Phe = 1.9 µM; Ki for compound 2 = 21 nM). (B) Noncompetitive binding with respect to ATP. Compound 2 concentrations were as follows: 0 µM (), 0.01 µM (), and 0.04 µM ().

Antibacterial activity. The phenyl-thiazolylurea-sulfonamides demonstrated significant antibacterial activity (Table 3). For example, compound 4 in a synthetic medium without Phe possessed submicromolar MICs for S. aureus (MIC = 0.4 µg/ml), S. pneumoniae (MIC = 0.8 µg/ml), H. influenzae (MIC = 0.4 µg/ml), and M. catarrhalis (MIC = 0.4 µg/ml). The antibacterial activity was partly antagonized by the addition of Phe to the culture broth. MICs of all compounds tested in the presence of 50 µM Phe increased by a factor of 2 to 4 for H. influenzae, M. catarrhalis, and S. pneumoniae. For S. aureus, this antagonism was more pronounced, with an 8-fold increase in MIC (Table 3). The effect of increasing the Phe concentrations in the culture medium on the antibacterial activity of the phenyl-thiazolylurea-sulfonamides was investigated in more detail (Fig. 3). The addition of up to 250 µM Phe antagonized the activity against the gram-negative pathogens H. influenzae and M. catarrhalis and the gram-positive bacterium S. pneumoniae only slightly, but a stronger effect was observed for S. aureus, especially at Phe concentrations above 50 µM (e.g., for compounds 4 and 5, MIC = 3 µg/ml at 50 µM Phe and MIC = 100 µg/ml at 100 µM Phe). Time-kill studies with S. pneumoniae demonstrated that the phenyl-thiazolylurea-sulfonamides act by a bacteriostatic mechanism (Fig. 4).

View this table: [in this window] [in a new window]

TABLE 3. Antimicrobial activity of selected phenyl-thiazolylurea-sulfonamides against major respiratory tract pathogens

View larger version (25K): [in this window] [in a new window]

FIG. 3. Effect of increasing Phe concentrations in the culture broth on the antibacterial activity of the phenyl-thiazolylurea-sulfonamides in vitro.

View larger version (12K): [in this window] [in a new window]

FIG. 4. Time-kill study. Effect of increasing concentrations of compound 5 on the number of CFU of S. pneumoniae G9A.

The MIC increase seen in the presence of extracellular Phe already suggested that the antibacterial mechanism of the phenyl-thiazolylurea-sulfonamides is based on inhibition of Phe-RS. To confirm the interference with this enzyme inside of the intact bacterial cell, we performed proteome analysis of B. subtilis after treatment with compound 1. Cytoplasmic proteins synthesized by the bacterium in response to the presence of the phenyl-thiazolylurea-sulfonamide were analyzed by two-dimensional polyacrylamide gel electrophoresis, and the results were compared with the proteome pattern of an untreated control (Table 4). The proteome signature of compound 1 included the induction of many proteins previously identified during norvaline (11) or mupirocin (5) treatment of B. subtilis, e.g., Ald, MinD, Spo0A, SpoVG, YurP, and YvyD. These proteins are known to be positively controlled by the stringent response in this organism (11). In addition, even the direct target, the -subunit of Phe-RS (PheS), was induced in phenyl-thiazolylurea-sulfonamide-treated cells. This is in contrast to the results seen with mupirocin, which (as expected) did not induce PheS but did induce the corresponding IleS and additional proteins of isoleucine-valine biosynthesis (5). In a further experiment, an E. coli strain carrying a relA mutation was used to investigate the effect of the stringent response on the activity of our compounds (Table 5). Mupirocin and all phenyl-thiazolylurea-sulfonamides were more potent with the relaxed strain (the relA mutant; strain CP79) incapable of the induction of the stringent response (12) than with the corresponding isogenic wild-type strain (relA⁺; strain CP78). For example, MICs of compound 3 with strains CP79 and CP78 were 0.003 and 0.2 µg/ml, respectively. This effect was even more pronounced for our Phe-RS inhibitors than for the Ile-RS inhibitor. In contrast, other protein synthesis inhibitors that did not induce the stringent response showed equal activities against both strains (Table 5). These results prove the nature of the anticipated mechanism of action. By inhibition of Phe-RS, the phenyl-thiazolylurea-sulfonamides lead to the accumulation of uncharged tRNA^Phe, which in turn triggers the induction of the stringent response.

View this table: [in this window] [in a new window]

TABLE 4. Proteome analysis of B. subtilisa

View this table: [in this window] [in a new window]

TABLE 5. Effect of the phenyl-thiazolylurea-sulfonamides on the susceptibility of a relA+ strain and its isogenic strain carrying a relA mutation

In vivo potency. To evaluate the influence of the Phe concentration in the blood on the activity of the phenyl-thiazolylurea-sulfonamides, mice were fed on a Phe-free diet and the concentration of free Phe in the plasma was monitored. The Phe level decreased from 70 µM at day 0 to 15 µM at day 5. When compound 2 (i.v. treatment with 100 mg/kg of body weight) was investigated in the murine S. aureus sepsis model with mice fed on a Phe-free diet for 5 days prior to infection, the bacterial titer in liver and spleen of these mice was significantly lower than the level seen with untreated control animals (Fig. 5A). A smaller decrease in CFU numbers was observed for regularly fed mice with a normal Phe blood level (70 µM), which is in accordance with the strong Phe antagonism against S. aureus observed with compound 2 in vitro.

View larger version (37K): [in this window] [in a new window]

FIG. 5. In vivo activity of the phenyl-thiazolylurea-sulfonamides. (A) S. aureus 133 sepsis in the mouse. Bacterial loads in the organs after i.v. treatment with 100 mg of compound 2/kg of body weight at 0.5 h after infection are indicated. Antibacterial activity was compared in mice on normal or phenylalanine-free diets, resulting in blood phenylalanine concentrations of 70 or 15 µM, respectively. (B) S. pneumoniae 1707/4 sepsis in regularly fed rats without Phe limitation and with normal Phe blood levels (63 µM). Bacterial titers in the organs after i.p. treatment with 100 mg of compound 4/kg at 0.5 and 3 h after infection are indicated. Five animals were employed per group. The results of statistical analyses performed using the Mann-Whitney test were calculated using GraphPad Prism software (version 3.02). *, statistically significant (P < 0.05).

Less-pronounced Phe antagonism was predicted from the in vitro data for the phenyl-thiazolylurea-sulfonamides and the pathogen S. pneumoniae (Table 3 and Fig. 3). Thus, we employed an S. pneumoniae sepsis model for further in vivo studies. In addition, we used a rat sepsis model (instead of a murine sepsis model) to circumvent the exceptionally high level of affinity of the phenyl-thiazolylurea-sulfonamides for mouse serum albumin. (MICs were lower in medium containing rat serum albumin than in medium containing mouse serum albumin and human serum albumin; data not shown.) When compound 4 was tested in rats with Phe blood levels of 63 µM and fed with regular food, after i.p. treatment with 100 mg/kg at 0.5 and 3 h after infection a decrease in CFU of 2 to 3 log₁₀ in the lung, kidney, and spleen was observed (Fig. 5B).

Top Abstract Introduction Materials and Methods Results Discussion References

 
aa-RSs are essential proteins in all living organisms (7). When one aa-RS is inhibited, the corresponding tRNA is not charged and is therefore unavailable for translation. This leads to protein synthesis inhibition, which in turn causes cell growth arrest. Consequently, each compound that inhibits any of the aa-RSs could be a potential antibacterial agent. We selected Phe-RS as a target, because the structures of the bacterial Phe-RSs are well conserved (39) but differ significantly from their eukaryotic counterparts (32). Phe-RS adopts a ₂ß₃ tetrameric structure in all prokaryotes and eukaryotic cytoplasmic sources known (13), and both subunits are required for aminoacylation of the tRNA. An exception to the tetrameric structures is the mitochondrial Phe-RS (34). The human mitochondrial Phe-RS enzyme is a small protein that is active as a monomer (8).

The aminoacylation reaction catalyzed by E. coli Phe-RS was used to screen our compound library. After initial hit identification, lead optimization yielded very potent phenyl-thiazolylurea-sulfonamides with IC₅₀s for E. coli and H. influenzae proteins in the low nanomolar range. IC₅₀s for Phe-RS derived from gram-positive bacteria (S. aureus and S. pneumoniae) were higher but still submicromolar. For comparison, mupirocin has IC₅₀s of 1.4 to 3 nM against Ile-RS derived from this panel of bacteria. Further investigation of the binding mode of the phenyl-thiazolylurea-sulfonamides to the E. coli enzyme demonstrated that these compounds bind competitively with respect to Phe. The inhibitory constant of compound 2 was 100-fold lower than the Michaelis-Menten constant (K_i = 21 nM; K_m = 1.8 µM), demonstrating that the phenyl-thiazolylurea-sulfonamides are potent inhibitors of the Phe-RS enzyme.

That we detected competitive inhibitors by our high-throughput screening might have been a consequence of the screening format employed (incorporation of radiolabeled Phe into ethanol-precipitable Phe-tRNA). This format dictated the use of limiting amounts of labeled Phe; consequently, the assay was relatively sensitive with respect to inhibitors which bind to the Phe-RS in a region that overlaps the Phe binding site. To circumvent potential selectivity issues with other ATP binding proteins, an excess of ATP was used in the high-throughput screening to minimize the number of compounds that bind to the ATP binding pocket of Phe-RS. Indeed, competition experiments demonstrated that ATP and phenyl-thiazolylurea-sulfonamides do not compete for the same binding site. The hypothesis that the phenyl-thiazolylurea-sulfonamides target the Phe binding site on the Phe-RS but not the ATP pocket was further strengthened by the results of experiments with a mutated E. coli Phe-RS enzyme in which Ala₂₉₄ was mutated to Gly (20, 22). This mutated protein binds para-chloro-Phe and para-bromo-Phe as substrates, whereas the wild-type protein does not bind these bulky Phe analogues. The authors speculate that Ala₂₉₄ is part of the Phe binding pocket and that the mutation enlarges the Phe binding cavity, a hypothesis which is supported by crystallographic data (26, 28). We used this mutant protein to test compounds in which the thiazolyl group was replaced by enlarged ring systems. A dramatic decrease in potency, with IC₅₀s in the millimolar range, was observed for piperazine and pyrimidine derivatives tested with the wild-type protein. The decrease in potency was less pronounced with the mutant protein, with IC₅₀s still in the submicromolar range (data not shown).

The phenyl-thiazolylurea-sulfonamides demonstrated high levels of selectivity for the bacterial Phe-RS proteins compared with the results seen with the mammalian counterparts. Human-mitochondrial Phe-RS was inhibited only at high concentrations, with selectivity indices ranging from 400 to >25,000 compared to the results seen with E. coli enzyme. The mammalian cytoplasmic Phe-RS was not inhibited at compound concentrations of up to 200 µM.

The growth of a broad spectrum of bacteria, including gram-positive and gram-negative pathogens, was prevented by the presence of the phenyl-thiazolylurea-sulfonamides. Drug MICs below 1 µg/ml were measured for Staphylococcus, Streptococcus, Haemophilus, and Moraxella strains in synthetic medium in the absence of Phe. In accordance with the competitive binding mode, the antibacterial activity was partially antagonized by the addition of Phe to the culture broth. The physiological Phe concentration in human blood ranges from 38 to 115 µM (10), with an average of 48 µM (30, 38). In the presence of physiological Phe concentrations, MICs of the phenyl-thiazolylurea-sulfonamides increased marginally for S. pneumoniae, H. influenzae, and M. catarrhalis; however, stronger antagonism was seen against S. aureus. Increases in MICs were also observed for mupirocin and the corresponding amino acid Ile (19, 41). For instance, Wilson and coworkers reported substantial antagonism after the addition of 1 mM Ile in investigations using the S. aureus strain Russel (MIC without Ile in the medium, 0.06 µg/ml; MIC in the presence of 1 mM Ile, 2 µg/ml) (41).

To assess the value of Phe-RS as a potential antibacterial target, it was important to validate that the observed antibacterial effect of the phenyl-thiazolylurea-sulfonamides was indeed mediated by the inhibition of Phe-RS activity in the intact bacterium. The MIC increase in the presence of external Phe, the induction of the stringent response in gram-positive bacteria, and the susceptibility increase of a gram-negative relA mutant demonstrate that inhibition of Phe-RS is the basis of the promising antibacterial in vitro activity. To evaluate in vivo efficacy, the activity of the compounds was investigated in two different infection models. The compounds showed activity in an S. aureus sepsis model with mice having reduced Phe blood levels and remarkable potency in an S. pneumoniae sepsis model in rats with physiological Phe concentrations.

In summary, the phenyl-thiazolylurea-sulfonamides are the most potent Phe-RS inhibitors described to date. They demonstrate good in vitro activity against a broad spectrum of bacterial pathogens and a high level of selectivity with respect to the mammalian Phe-RS enzymes. The potential use of the phenyl-thiazolylurea-sulfonamides as antibacterial agents and the value of Phe-RS as a target in antibacterial therapy are supported by the in vivo activity of this class of compounds.

 
We emphasize our appreciation for excellent technical assistance by S. Cerezo-Galvez, B. Dethlefsen, E. Eisfelder, A. Gräwinger, M. Groth, L. Jansen, M. Korkowski, M. Oberborbeck, S. Obertegger, C. Oschwald, R. Pech, A. Polaczyk, U. Sauer, M. Schettler, P. Schneiders, R. Spang, P. Surdakowski, and C. Wilkop (Bayer AG, Pharma Research). In addition, we gratefully acknowledge W. Stirtan and J. Landro (Bayer Corp.) for performing the Phe-RS high-throughput screening and W. Schroeder (Bayer AG) for the determination of the Phe levels in the murine plasma. Furthermore, we thank J.-V. Höltje (Max-Planck-Institute Tübingen, Tübingen, Germany) for providing the E. coli strains CP78 and CP79, Michael Ibba (Ohio State University, Columbus) for the Gly₂₉₄ mutant and wild-type E. coli Phe-RS proteins, Linda Spremulli (University of Texas, San Antonio) for the human mt-Phe-RS overproducing plasmid pArgU218, H. Labischinski (Bayer AG) and M. Hecker (University of Greifswald) for helpful discussions, and G. Hewlett (Bayer AG) for critically reading the manuscript.

 
* Corresponding author. Mailing address: Bayer Healthcare AG, Antibacterial Research, Pharma Research Center, Aprather Weg 18a, D-42096 Wuppertal, Germany. Phone: (49) 202 364561. Fax: (49) 202 364116. E-mail: heike.broetz-oesterhelt.hb{at}bayer-ag.de.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Anderson, R. T., Jr., and D. V. Santi. 1976. Phenylalanyl transfer ribonucleic acid synthetase from Escherichia coli B. Potent inhibition by analogues of N-benzyl-2-phenylethylamine. J. Med. Chem. 19:1270-1275.[CrossRef][Medline]
2
2. Appelbaum, P. C. 2002. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. Dis. 34:1613-1620.[CrossRef][Medline]
3
3. Baines, P. J., D. Jackson, G. Mellows, A. J. Swaisland, and T. C. G. Tasker. 1984. Mupirocin: its chemistry and metabolism. R. Soc. Med. Int. Congr. Symp. Ser. 80:13-22.
4
4. Baltzinger, M., and E. Holler. 1982. Catalytic mechanism of phenylalanyl-tRNA synthetase of Escherichia coli K10. Conformational change and tRNAPhe phenylalanylation are concerted. Biochemistry 21:2467-2476.[CrossRef][Medline]
5
5. Bandow, J. E., H. Brötz, L. I. Leichert, H. Labischinski, and M. Hecker. 2003. Proteomic approach to understanding antibiotic action. Antimicrob. Agents Chemother. 47:948-955.[Abstract/Free Full Text]
6
6. Beaulieu, D., and K. A. Ohemeng. 1999. Patents on bacterial tRNA synthetase inhibitors: January 1996 to March 1999. Expert Opin. Investig. Patents 9:1021-1028.[CrossRef]
7
7. Brown, J. R., and W. F. Doolittle. 1995. Root of the universal tree of life based on ancient aminoacyl-tRNA synthetase gene duplications. Proc. Natl. Acad. Sci. USA 92:2441-2445.[Abstract/Free Full Text]
8
8. Bullard, J. M., Y. C. Cai, B. Demeler, and L. L. Spremulli. 1999. Expression and characterization of a human mitochondrial phenylalanyl-tRNA synthetase. J. Mol. Biol. 288:567-577.[CrossRef][Medline]
9
9. Conway, T. W., E. M. Lansford, Jr., and W. Shine. 1966. Purification and substrate specificity of a phenylalanine-activating enzyme from Escherichia coli 9723. J. Biol. Chem. 237:2850-2854.
10
10. Dickinson, J. C., H. Rosenblum, and P. B. Hamilton. 1965. Ion exchange chromatography of the free amino acids in the plasma of the newborn infant. Pediatrics 36:2-13.[Abstract/Free Full Text]
11
11. Eymann, C., G. Homuth, C. Scharf, and M. Hecker. 2002. Bacillus subtilis functional genomics: global characterization of the stringent response by proteome and transcriptome analysis. J. Bacteriol. 184:2500-2520.[Abstract/Free Full Text]
12
12. Fiil, N., and J. D. Friesen. 1968. Isolation of "relaxed" mutants of Escherichia coli. J. Bacteriol. 95:729-731.[Free Full Text]
13
13. Francklyn, C., K. Musier-Forsyth, and S. A. Martinis. 1997. Aminoacyl-tRNA synthetases in biology and disease: new evidence for structural and functional diversity in an ancient family of enzymes. RNA 3:954-960.[Medline]
14
14. Fraser, T. H., and A. Rich. 1975. Amino acids are not all initially attached to the same position on transfer RNA molecules. Proc. Natl. Acad. Sci. USA 72:3044-3048.[Abstract/Free Full Text]
15
15. Fuller, A. T., G. Mellows, M. Woolford, G. T. Banks, K. D. Barrow, and E. B. Chain. 1971. Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens. Nature 234:416-417.[CrossRef][Medline]
16
16. Gallant, P., J. Finn, D. Keith, and P. Wendler. 2000. The identification of quality antibacterial drug discovery targets: a case study with aminoacyl-tRNA synthetases. Emerg. Ther. Targets 4:1-9.
17
17. Goldgur, Y., L. Mosyak, L. Reshetnikova, V. Ankilova, O. Lavrik, S. Khodyreva, and M. Safro. 1997. The crystal structure of phenylalanyl-tRNA synthetase from thermus thermophilus complexed with cognate tRNAPhe. Structure 5:59-68.[Medline]
18
18. Hiramatsu, K., K. Okuma, X. X. Ma, M. Yamamoto, S. Hori, and M. Kapi. 2002. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr. Opin. Infect. Dis. 15:407-413.[Medline]
19
19. Hughes, J., and G. Mellows. 1978. Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem. J. 176:305-318.[Medline]
20
20. Ibba, M., C. M. Johnson, H. Hennecke, and A. R. Fersht. 1995. Increased rates of tRNA charging through modification of the enzyme-aminoacyl-adenylate complex of phenylalanyl-tRNA synthetase. FEBS Lett. 358:293-296.[CrossRef][Medline]
21
21. Ibba, M., P. Kast, and H. Hennecke. 1994. Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase. Biochemistry 33:7107-7112.[CrossRef][Medline]
22
22. Kast, P., and H. Hennecke. 1991. Amino acid substrate specificity of Escherichia coli phenylalanyl-tRNA synthetase altered by distinct mutations. J. Mol. Biol. 222:99-124.[CrossRef][Medline]
23
23. Konrad, I., and R. Roschenthaler. 1977. Inhibition of phenylalanine tRNA synthetase from Bacillus subtilis by ochratoxin A. FEBS Lett. 83:341-347.[CrossRef][Medline]
24
24. Lacks, S., and R. D. Hotchkiss. 1960. A study of the genetic material determining an enzyme activity in Pneumococcus. Biochim. Biophys. Acta 39:508-518.[Medline]
25
25. Liu, H. 2001. Measurement of blood plasma amino acids in ultrafiltrates by high performance liquid chromatography with automatic precolumn O-phthaldialdehyde derivatization. Methods Mol. Biol. 159:123-140.
26
26. Lombardo, B., G. Raimo, and V. Bocchini. 2002. Molecular and functional properties of an archaeal phenylalanyl-tRNA synthetase from the hyperthermophile Sulfolobus solfataricus. Biochim. Biophys. Acta 1596:246-252.[CrossRef][Medline]
27
27. Miller, D., V. Urdaneta, and A. Weltman. 2002. Public health dispatch: vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. Morb. Mortal. Wkly. Rep. 51:902.[Medline]
28
28. Mosyak, L., L. Reshetnikova, Y. Goldgur, M. Delarue, and M. G. Safro. 1995. Structure of phenylalanyl-tRNA synthetase from Thermus thermophilus. Nat. Struct. Biol. 2:537-547.[CrossRef][Medline]
29
29. Nathans, D., and F. Lipmann. 1961. Amino acid transfer from aminoacyl-ribonucleic acids to protein on ribosomes of Escherichia coli. Biochemistry 47:497-504.
30
30. Proenza, A. M., A. Palou, and P. Roca. 1994. Amino acid distribution in human blood. A significant pool of amino acids is adsorbed onto blood cell membranes. Biochem. Mol. Biol. Int. 34:971-982.[Medline]
31
31. Reshetnikova, L., N. Moor, O. Lavrik, and D. G. Vassylyev. 1999. Crystal structures of phenylalanyl-tRNA synthetase complexed with phenylalanine and a phenylalanyl-adenylate analogue. J. Mol. Biol. 287:555-568.[CrossRef][Medline]
32
32. Rodova, M., V. Ankilova, and M. G. Safro. 1999. Human phenylalanyl-tRNA synthetase: cloning, characterization of the deduced amino acid sequences in terms of the structural domains and coordinately regulated expression of the alpha and beta subunits in chronic myeloid leukemia cells. Biochem. Biophys. Res. Commun. 255:765-773.[CrossRef][Medline]
33
33. Roth, A., G. Eriani, G. Dirheimer, and J. Gangloff. 1993. Kinetic properties of pure overproduced Bacillus subtilis phenylalanyl-tRNA synthetase do not favour its in vivo inhibition by ochratoxin A. FEBS Lett. 326:87-91.[CrossRef][Medline]
34
34. Sanni, A., P. Walter, Y. Boulanger, J. P. Ebel, and F. Fasiolo. 1991. Evolution of aminoacyl-tRNA synthetase quaternary structure and activity: Saccharomyces cerevisiae mitochondrial phenylalanyl-tRNA synthetase. Proc. Natl. Acad. Sci. USA 88:8387-8391.[Abstract/Free Full Text]
35
35. Santi, D. V., and R. W. Webster, Jr. 1976. Phenylalanyl transfer ribonucleic acid synthetase from rat liver. Analysis of phenylalanine and adenosine 5'-triphosphate binding sites and comparison to the enzyme from Escherichia coli. J. Med. Chem. 19:1276-1279.[CrossRef][Medline]
36
36. Schimmel, P., J. Tao, and J. Hill. 1998. Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J. 12:1599-1609.[Abstract/Free Full Text]
37
37. Sievert, D. M., M. L. Boulton, G. Stoltman, D. Johnson, M. G. Stobierski, F. P. Downes, P. A. Somsel, J. T. Rudrik, W. Brown, W. Hafeez, T. Lundstrom, E. Flanagan, R. Johnson, J. Mitchell, and S. Chang. 2002. Staphylococcus aureus resistant to vancomycin—United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.[Medline]
38
38. Soupart, P. 1962. Free amino acids of blood and urine in the human, p. 220-262. In J. T. Holden (ed.), Amino acid pools. Elsevier, Amsterdam, The Netherlands.
39
39. Symanski, M., M. A. Deniziak, and J. Barciszewski. 2001. Aminoacyl-tRNA Synthetases database. Nucleic Acids Res. 29:288-290.[Abstract/Free Full Text]
40
40. Tao, J., and P. Schimmel. 2000. Inhibitors of aminoacyl-tRNA synthetases as novel anti-infectives. Expert Opin. Investig. Drugs 9:1767-1775.[CrossRef][Medline]
41
41. Wilson, J. M., B. Oliva, R. Cassels, P. J. O'Hanlon, and I. Chopra. 1995. SB 205952, a novel semisynthetic monic acid analog with at least two modes of action. Antimicrob. Agents Chemother. 39:1925-1933.[Abstract]
42
42. World Health Organization. 2001. Global strategy for containment of antimicrobial resistance: CDS/CSR/DRS/2001.2. World Health Organization, Geneva, Switzerland.

---

Antimicrobial Agents and Chemotherapy, February 2004, p. 525-532, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.525-532.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Hurdle, J. G., O'Neill, A. J., Chopra, I. (2005). Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob. Agents Chemother. 49: 4821-4833 [Full Text]  
• Freiberg, C., Fischer, H. P., Brunner, N. A. (2005). Discovering the Mechanism of Action of Novel Antibacterial Agents through Transcriptional Profiling of Conditional Mutants. Antimicrob. Agents Chemother. 49: 749-759 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beyer, D. Articles by Brötz-Oesterhelt, H. Search for Related Content PubMed PubMed Citation Articles by Beyer, D. Articles by Brötz-Oesterhelt, H.